Finance

Lists
Why is PMVP down 2.16%?
Dive Deeper
PMVP:NASDAQ
PMV Pharmaceuticals Inc
$1.36
-2.16%
(-0.030) 1D
Oct 21, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PMVP...
Open
$1.37
High
$1.41
Low
$1.35
Mkt. cap
102.70M
Avg. vol.
799.10K
Volume
0.00
52-wk high
$1.91
52-wk low
$1.02
EPS
-$1.41
Beta
1.36
Shares outstanding
75.51M
No. of employees
54
Open
$1.37
High
$1.41
Low
$1.35
Mkt. cap
102.70M
Avg. vol.
799.10K
Volume
0.00
52-wk high
$1.91
52-wk low
$1.02
EPS
-$1.41
Beta
1.36
Shares outstanding
75.51M
No. of employees
54
News stories
From web sources and news partners
About PMV Pharmaceuticals Inc
CEO-
Employees54
Founded2013
Headquarters-
SectorBiotechnology
Websitepmvpharma.com
Analyst ratings
Based on 5 analysts giving stock ratings to PMVP in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for PMVP in the last 3 months.
Highest
Current $1.36
$5.00 (+267.65%)
Average
$4.20 (+208.82%)
Lowest
$3.00 (+120.59%)
Analyst
Recommendation
Action
Price target
Projected
Date
Robert Burns
H.C. Wainwright
Buy
Reiterated
$5.00
+267.6%
09/08/2026
Unknown Analyst
Craig-Hallum
Buy
Reiterated
$4.00
+194.1%
09/01/2026
Jonathan Miller
Evercore ISI
Buy
Maintained
$4.00
+194.1%
09/01/2026
Jay Olson
Oppenheimer
Buy
Reiterated
$5.00
+267.6%
09/01/2026
Jeff Jones
Oppenheimer
Buy
Reiterated
$5.00
+267.6%
09/01/2026
Unknown Analyst
Ladenburg Thalmann & Co.
Buy
Reiterated
$3.00
+120.6%
08/17/2026
Rick Bienkowski
Ladenburg Thalmann & Co.
Buy
Reiterated
$3.00
+120.6%
08/17/2026
Yaron Werber
TD Cowen
Buy
Maintained
-
-
05/12/2026
Albert Lowe
Craig-Hallum
Buy
Maintained
$4.00
+194.1%
11/13/2025
Last report
Aug 14, 2026
Fiscal period
Q2 2026
-$0.34 / -$0.40
+15.00%beat
Revenue / Est. (USD)
- / 0.00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
18.21M
15.83M
15.33M
14.68M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.31M
3.42M
3.69M
4.20M
Operating expense
22.52M
19.24M
19.02M
18.88M
Total operating expenses
22.52M
19.24M
19.02M
18.88M
Operating income
-22.52M
-19.24M
-19.02M
-18.88M
Other non operating income
-23.00K
-1.00K
1.00K
10.00K
EBT including unusual items
-21.06M
-18.01M
-18.04M
-18.08M
EBT excluding unusual items
-21.06M
-18.01M
-18.04M
-18.08M
Income tax expense
-6.00K
26.00K
-
3.00K
Effective tax rate
0.03%
-0.14%
-
-0.02%
Other operating expenses
-
-
-
-
Net income
-21.06M
-18.04M
-18.04M
-18.09M
Net profit margin
-
-
-
-
Earnings per share
-0.40
-0.34
-0.34
-0.34
Interest and investment income
1.48M
1.23M
980.00K
788.00K
Interest expense
-
-
-
-
Net interest expenses
1.48M
1.23M
980.00K
788.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-22.49M
-19.21M
-18.98M
-18.86M
Gain or loss from assets sale
-1.00K
-
-
25.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps